Balanced news tone
News Sentiment
BOT sentiment intelligence
Botanix Pharmaceuticals Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
90/100 classification confidence.
directly relevant articles
high-authority source matches
+14.3% over one week, +4.3% over four weeks, trend inactive, and below fair value.
Botanix Pharmaceuticals (ASX:BOT) Leads a New ASX Penny Stocks Focus
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Botanix Pharmaceuticals (ASX:BOT) Leads a New ASX Penny Stocks Focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 12:01
- Source
- Kalkine Media
Botanix Pharmaceuticals (ASX:BOT): Why Do Biotech Milestones Matter?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 08:37
- Source
- Kalkine Media
Botanix Pharmaceuticals (ASX: BOT) Stays Hot as Biotech Traders Debate the Next Catalyst
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Kalkine
Botanix Pharmaceuticals (ASX:BOT): Healthcare Stock Keeps Traders Watching Beyond the Chart
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Kalkine
Evaluating Botanix Pharmaceuticals (ASX:BOT) After A$45 Million Equity Raise For Sofdra Rollout
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Feb 2026 08:00
- Source
- Market source
A Look At Botanix Pharmaceuticals (ASX:BOT) Valuation After Its A$45m Follow On Equity Offerings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2026 08:00
- Source
- simplywall.st
Botanix raises $45m to fuel Sofdra growth and secure global supply chain
- Tone
- Positive 82/100
- Event
- Macro sensitivity
- Published
- 17 Feb 2026 08:00
- Source
- BiotechDispatch
We Think Botanix Pharmaceuticals (ASX:BOT) Needs To Drive Business Growth Carefully
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Nov 2025 08:00
- Source
- Market source
Insights: Botanix Pharmaceuticals Ltd (ASX:BOT)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Oct 2025 02:06
- Source
- smallcaps.com.au
Will Botanix Pharmaceuticals’ (ASX:BOT) Investor Outreach Reinforce Management Credibility or Raise Fresh Questions?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Oct 2025 07:00
- Source
- simplywall.st
Botanix Pharmaceuticals (ASX:BOT): Evaluating Valuation as Management Updates and Sofdra Launch Draw Investor Focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Oct 2025 07:00
- Source
- Market source
While Botanix Pharmaceuticals (ASX:BOT) shareholders have made 123% in 3 years, increasing losses might now be front of mind as stock sheds 12% this week
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 10 Oct 2025 07:00
- Source
- simplywall.st
Analysts Expect Breakeven For Botanix Pharmaceuticals Limited (ASX:BOT) Before Long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Oct 2025 07:00
- Source
- Market source
Gilbert + Tobin advises Botanix Pharmaceuticals Limited on cross-border debt facility with Kreos Capital
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 25 Jun 2025 07:00
- Source
- Gilbert + Tobin